---
layout: post
title: New Drug Approvals 2013 - Pt. V - Canagliflozin (INVOKANA™)
date: '2013-04-16T17:37:00.003+01:00'
author: Gerard JP van Westen
tags:
- Oral Drugs
- Small Molecule Drugs
- 2013 New Drugs
- First-in-class Drugs
modified_time: '2013-04-16T17:37:57.637+01:00'
thumbnail: http://3.bp.blogspot.com/-_wyiIW3qB6k/UWVgWG4VPvI/AAAAAAAAHcE/Nh0BqOu0_ew/s72-c/invokana_logo.png
blogger_id: tag:blogger.com,1999:blog-2546008714740235720.post-7173684135988075419
blogger_orig_url: http://chembl.blogspot.com/2013/04/new-drug-approvals-2013-pt-v.html
---

<div dir="ltr" style="text-align: left;" trbidi="on">
<div class="separator" style="clear: both; text-align: center;">
<a href="http://3.bp.blogspot.com/-_wyiIW3qB6k/UWVgWG4VPvI/AAAAAAAAHcE/Nh0BqOu0_ew/s1600/invokana_logo.png" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" height="113" src="http://3.bp.blogspot.com/-_wyiIW3qB6k/UWVgWG4VPvI/AAAAAAAAHcE/Nh0BqOu0_ew/s320/invokana_logo.png" width="320" /></a></div>
<div class="separator" style="clear: both; text-align: center;">
<br /></div>
<div class="separator" style="clear: both; text-align: center;">
<a href="https://www.ebi.ac.uk/chembltools/autoiconlarge2/1,1,1,2,0,1,0,0,1,1" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" height="41" src="https://www.ebi.ac.uk/chembltools/autoiconlarge2/1,1,1,2,0,1,0,0,1,1" width="400" /></a></div>
<div style="text-align: center;">
<b><br /></b>
<b>ATC Code: </b><a href="http://www.whocc.no/atc_ddd_index/?code=A10BX">A10BX</a> <i>(incomplete)</i></div>
<div style="text-align: center;">
<b>Wikipedia:</b>&nbsp;<a href="http://en.wikipedia.org/wiki/Canagliflozin">Canagliflozin</a></div>
<div style="text-align: center;">
<b>ChEMBL:&nbsp;</b><span style="text-align: left;"><a href="https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2048484">CHEMBL2048484</a></span></div>
<br />
<div style="text-align: left;">
On March 29th the <a href="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm345848.htm">FDA approved</a> <a href="http://en.wikipedia.org/wiki/Canagliflozin">Canagliflozin</a> (trade name&nbsp;<a href="http://www.invokana.com/">INVOKANA</a>™) to improve glycemic control for the treatment of diabetes type 2.&nbsp;Canagliflozin is to&nbsp;be used in combination with proper diet and&nbsp;exercise.&nbsp;Canagliflozin is a subtype 2 <a href="http://en.wikipedia.org/wiki/Sodium-glucose_transport_proteins">sodium-glucose transport protein</a> (<a href="http://en.wikipedia.org/wiki/SLC5A2">SGLT2</a>, <a href="https://www.ebi.ac.uk/chembl/target/inspect/CHEMBL3884">ChEMBL3884</a>) inhibitor.&nbsp;Canagliflozin&nbsp;is a first-in-class drug with several others still in <a href="http://en.wikipedia.org/wiki/SLC5A2">clinical trials</a>.&nbsp;</div>
<div style="text-align: left;">
<br />
<b>Target</b></div>
<div style="text-align: left;">
SGLT2 is found in the proximal tubule of the nephron in the kidneys (as is paralog&nbsp;<a href="http://en.wikipedia.org/wiki/SLC5A1">SGLT1</a>, <a href="https://www.ebi.ac.uk/chembl/target/inspect/CHEMBL4979">ChEMBL4979</a>). SGLT2 one of the 5 known members of the sodium-glucose transporter proteins family. The transporter is responsible for 90 % of the total <a href="http://www.ncbi.nlm.nih.gov/pubmed/11133510">renal glucose reuptake</a>&nbsp;(corresponding to 98 % of the uptake in the proximal convoluted tubule). The protein has a relatively low affinity for glucose compared to SGLT1 (<a href="http://www.ncbi.nlm.nih.gov/pubmed/17653207">2 mM&nbsp;versus 0.4 mM</a>) but a higher capacity. Hence inhibition of this protein leads to a lowering of the glucose plasma concentration. SGLT2 is a 672 amino acid protein which can be found on Uniprot (<a href="http://www.uniprot.org/uniprot/P31639">P31639</a>). The most similar PDB structure is the sodium/glucose costransporter from <i>Vibrio parahaemolyticus</i> (<a href="http://www.pdb.org/pdb/explore/explore.do?structureId=3DH4">3DH4</a>).&nbsp;</div>
<div style="text-align: left;">
<br /></div>
<div style="text-align: left;">
The paralog SGLT1 (664 amino acids, 57.63% identical to SGLT2) is also found <a href="http://www.ncbi.nlm.nih.gov/pubmed/20385036">in the intestine where it is responsible for glucose uptake</a>. Hence SGLT1 forms an important anti-target for Canagliflozin.&nbsp;</div>
<div style="text-align: left;">
<br />
<b>Structure</b></div>
<div class="separator" style="clear: both; text-align: center;">
<a href="http://1.bp.blogspot.com/-SmGfGlm2VL0/UWVyN7b8wvI/AAAAAAAAHco/uFliHCbaqPo/s1600/1351917.png" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" height="400" src="http://1.bp.blogspot.com/-SmGfGlm2VL0/UWVyN7b8wvI/AAAAAAAAHco/uFliHCbaqPo/s400/1351917.png" width="400" /></a></div>
<div style="text-align: left;">
Canagliflozin (<a href="https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2048484">CHEMBL2048484</a>&nbsp;;&nbsp;Chemspider : <a href="http://www.chemspider.com/Chemical-Structure.26333259">26333259</a>&nbsp;;&nbsp;&nbsp;Pubchem : <a href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=125299338">125299338</a>&nbsp;; Unichem Identifier 1075025) is a small molecule drug with a molecular weight of 444.5 Da, an AlogP of 3.45, 5 rotatable bonds and does not violate the rule of 5.</div>
<div style="text-align: left;">
<b><br />
</b></div>
<div style="text-align: left;">
<b>Canonical SMILES</b>&nbsp;: Cc1ccc(cc1Cc2ccc(s2)c3ccc(F)cc3)[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O</div>
<b><br />
</b> <b>InChi</b>: InChI=1S/C24H25FO5S/c1-13-2-3-15(24-23(29)22(28)21(27)19(12-26)30-24)10-16(13)11-18-8-9-20(31-18)14-4-6-17(25)7-5-14/h2-10,19,21-24,26-29H,11-12H2,1H3/t19-,21-,22+,23-,24+/m1/s1<br />
<div>
<br />
<b>Contra-indications</b></div>
<div>
<div>
Canagliflozin is contra-indicated when there is a history of serious hypersensitivity reactions to&nbsp;Canagliflozin&nbsp;or in cases of severe renal impairment, ESRD, or on dialysis.</div>
</div>
<div>
<br />
<b>Dosage</b></div>
The recommended starting dose of Canagliflozin is 100 mg once daily, taken before the first meal of the day. The dose can be increased to 300 mg once daily in patients tolerating Canagliflozin. 100 mg should be dosed once daily who have an eGFR of 60 mL/min/1.73 m<sup>2</sup> or greater and require additional glycemic control. Canagliflozin is limited to 100 mg once daily in patients who have an eGFR of 45 to less than 60 mL/min/1.73 m<sup>2</sup>.Canagliflozin should be discontinued if eGFR falls below 45 mL/min/1.73 m<sup>2</sup>.<br />
<br />
<b>Metabolism</b><br />
O-glucuronidation is the major metabolic elimination pathway for canagliflozin, which is mainly glucuronidated by UGT1A9 and UGT2B4 to two inactive O-glucuronide metabolites. CYP3A4-mediated (oxidative) metabolism of canagliflozin is minimal (approximately 7%) in humans.<br />
<br />
<b>Excretion</b><br />
Following administration of a single oral [<sup>14</sup>C]canagliflozin dose to healthy subjects, 41.5%, 7.0%, and 3.2% &nbsp;of the administered radioactive dose was recovered in feces as canagliflozin, a hydroxylated metabolite, and an O-glucuronide metabolite, respectively. Enterohepatic circulation of canagliflozin was negligible. Approximately 33% of the administered radioactive dose was excreted in urine, mainly as O-glucuronide metabolites (30.5%). Less than 1% of the dose was excreted as unchanged canagliflozin in urine. Renal clearance of canagliflozin 100 mg and 300 mg doses ranged from 1.30 to 1.55 mL/min. Mean systemic clearance of canagliflozin was approximately 192 mL/min in healthy subjects following intravenous administration.<br />
<br />
The license holder is <a href="http://www.janssenpharmaceuticalsinc.com/">Janssen Pharmaceuticals, Inc.</a> and the full prescribing information can be found <a href="http://www.invokanahcp.com/prescribing-information.pdf">here</a>.</div>
